2D 1H-13C high res (L/V methyl stereospecific assignment)
1
14
1
3D (H)CCH-TOCSY
1
15
1
3D (H)CCH-COSY
1
16
1
3D (H)CCH-TOCSY
1
17
1
3D 1H-13C NOESY aromatic
-
試料調製
詳細
Solution-ID
内容
溶媒系
1
5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C.003, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O, 95% H2O/5% D2O
95% H2O/5% D2O
2
5.0 mg/mL [U-100% 13C; U-100% 15N] HR8910C, 15.0 mg/mL HR8910C, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O, 1 x Proteinase Inhibitors, 95% H2O/5% D2O
95% H2O/5% D2O
3
0.3 mM [U-100% 15N] HR8910C, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O, 1 x Proteinase Inhibitors, 4.2 % PEG, 95% H2O/5% D2O
95% H2O/5% D2O
4
5.0 mg/mL [U-5% 13C; U-100% 15N] HR8910C.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 5 % D2O, 95% H2O/5% D2O
95% H2O/5% D2O
試料
濃度 (mg/ml)
構成要素
Isotopic labeling
Solution-ID
5.0mg/mL
HR8910C.003-1
[U-100% 13C; U-100% 15N]
1
1 %
Proteinase Inhibitors-2
1
0.02 %
NaN3-3
1
10mM
DTT-4
1
5mM
CaCL2-5
1
200mM
NaCL-6
1
20mM
MES pH 6.5-7
1
5 %
D2O-8
1
5.0mg/mL
HR8910C-9
[U-100% 13C; U-100% 15N]
2
15.0mg/mL
HR8910C-10
2
0.02 %
NaN3-11
2
10mM
DTT-12
2
5mM
CaCL2-13
2
200mM
NaCL-14
2
20mM
MES pH 6.5-15
2
5 %
D2O-16
2
1 %
Proteinase Inhibitors-17
2
0.3mM
HR8910C-18
[U-100% 15N]
3
0.02 %
NaN3-19
3
10mM
DTT-20
3
5mM
CaCL2-21
3
200mM
NaCL-22
3
20mM
MES pH 6.5-23
3
5 %
D2O-24
3
1 %
Proteinase Inhibitors-25
3
4.2 %
PEG-26
3
5.0mg/mL
HR8910C.005-27
[U-5% 13C; U-100% 15N]
4
1 %
Proteinase Inhibitors-28
4
0.02 %
NaN3-29
4
10mM
DTT-30
4
5mM
CaCL2-31
4
200mM
NaCL-32
4
20mM
MES pH 6.5-33
4
5 %
D2O-34
4
試料状態
pH: 6.5 / 圧: ambient / 温度: 298 K
-
NMR測定
NMRスペクトロメーター
タイプ: Bruker Avance / 製造業者: Bruker / モデル: AVANCE / 磁場強度: 800 MHz
-
解析
NMR software
名称
バージョン
開発者
分類
CNS
1.3
Brunger, Adams, Clore, Gros, NilgesandRead
refinement,structuresolution,geometryoptimization
CYANA
3.02
Guntert, MumenthalerandWuthrich
refinement,geometryoptimization,structuresolution
AutoAssign
2.1
Zimmerman, Moseley, KulikowskiandMontelione
dataanalysis,chemicalshiftassignment
NMRPipe
2
Delaglio, Grzesiek, Vuister, Zhu, PfeiferandBax
解析
TopSpin
2.1
BrukerBiospin
collection
PINE
1
Bahrami, Markley, Assadi, andEghbalnia
chemicalshiftassignment
Sparky
3.112
Goddard
データ解析
TALOS+
Shen, Cornilescu, DelaglioandBax
geometryoptimization
PALES
PALES (Zweckstetter, Bax)
geometryoptimization
PSVS
1.4
Bhattacharya, Montelione
structurevalidation
CNS
1.3
Brunger, Adams, Clore, Gros, NilgesandRead
精密化
精密化
手法: simulated annealing / ソフトェア番号: 1 詳細: Structure determination of this symmetric homodimer was performed iteratively using CYANA 3.02. The 20 structures out of 100 with lowest target function were further refined by restrained ...詳細: Structure determination of this symmetric homodimer was performed iteratively using CYANA 3.02. The 20 structures out of 100 with lowest target function were further refined by restrained molecular dynamics/energy minimization in explicit water using CNS 1.3. Residual dipolar couplings and backbone dihedral angle constraints for the ordered regions were applied at all stages of the structure determination
NMR constraints
NOE constraints total: 1914 / NOE intraresidue total count: 437 / NOE long range total count: 476 / NOE medium range total count: 523 / NOE sequential total count: 478 / Protein phi angle constraints total count: 50 / Protein psi angle constraints total count: 51
代表構造
選択基準: lowest energy
NMRアンサンブル
コンフォーマー選択の基準: structures with the lowest energy 計算したコンフォーマーの数: 100 / 登録したコンフォーマーの数: 20